Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)

M. van Manen (Rotterdam, Netherlands), S. Birring (London, United Kingdom), C. Vancheri (Catania, Italy), A. Odink (Rotterdam, Netherlands), B. Hussain (Rotterdam, Netherlands), V. Vindigni (Catania, Italy), E. Renzoni (London, United Kingdom), A. Russell (London, United Kingdom), M. Wapenaar (Rotterdam, Netherlands), V. Cottin (Lyon, France), M. Wijsenbeek (Rotterdam, Netherlands)

Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Session: The world of idiopathic pulmonary fibrosis
Session type: Poster Discussion
Number: 1729
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. van Manen (Rotterdam, Netherlands), S. Birring (London, United Kingdom), C. Vancheri (Catania, Italy), A. Odink (Rotterdam, Netherlands), B. Hussain (Rotterdam, Netherlands), V. Vindigni (Catania, Italy), E. Renzoni (London, United Kingdom), A. Russell (London, United Kingdom), M. Wapenaar (Rotterdam, Netherlands), V. Cottin (Lyon, France), M. Wijsenbeek (Rotterdam, Netherlands). Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF). 1729

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Relationship between chronic dyspnoea and indices of disease severity in idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 150s
Year: 2001

Respiratory infections in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009

Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017

Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016


Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020

Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity
Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)?
Year: 2018

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
Year: 2017



Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 1067-1072
Year: 2010



Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012


Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010

Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007

Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2002; 20: Suppl. 38, 354s
Year: 2002

Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018


Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018

Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016


Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020